Editorial: Novelties in acute myeloid leukemia: from biology to clinical applications
Luca Vincenzo Cappelli,Nico Gagelmann,Hassan Awada,Carmelo Gurnari
DOI: https://doi.org/10.3389/fonc.2024.1499272
IF: 4.7
2024-10-18
Frontiers in Oncology
Abstract:In the last decade, tremendous advances have revolutionized the biological landscape of acute myeloid leukemia (AML). The application of sophisticated molecular biology tools has unveiled a plethora of (epi)genomic and transcriptomic alterations, some of which have been recently recognized in pre-leukemic conditions (e.g. clonal hematopoiesis of indeterminate potential -CHIP 1 ) with implications on AML ontogenesis and prognosis, paving the way for targeted approaches. The most recent diagnostic and prognostic schemes have included these latest advances 2 , further improving the clinical management of AML patients.The present Research Topic has provided a glimpse on some of these aspects, including: 1) new insights on AML biology, with the identification of novel transcriptomic signatures affecting prognosis, mechanistic description of pathogenic mutations (i.e. RAS) and oncogenic fusions (SET-CAN/NUP214) and the recent discoveries on leukemia stem cells (LSCs) at single-cell resolution; 2) new therapeutic perspectives in either induction (lowerdose chemotherapy + venetoclax or alternative chemotherapies for mixed phenotype acute leukemia -MPAL) or relapsed/refractory (R/R) AML (venetoclax + hypomethylating agents -HMA, targeted agent Selinexor, CAR-T cells). As a result, a balanced selection of articles spanning from AML biology and novel prognostic indicators to innovative therapeutic strategies has been selected for the readers.Regarding AML biology, Villar S. and colleagues analyzed the transcriptome of 224 AML patients > 65 years-old at diagnosis treated in the Spanish PETHEMA-FLUGAZA clinical trial in order to identify new prognostic biomarkers in this population. They identified a specific transcriptomic signature for high-risk patients, revealing that low expression of B7H3 gene with high expression of BANP gene identifies a subset with a more favorable prognosis surviving more than 12 months. This result was further validated in the BEAT AML cohort.Zhang J. et al focused on autophagy, since beside being known as a natural cellular response to a wide spectrum of cellular processes, it is debated whether it might have a pathogenic role in leukemias and particularly in AML. The authors found >100 differentially expressed genes (DEGs) related to autophagy between AML and healthy controls. Next, they selected 12 of these genes and developed a prognostic model predictive for survival of AML patients in both TCGA data and independent AML cohorts from GEO databases.Wan P. et al in a first-time approach based on the differential expression of lysosomerelated genes in AML identified two different subtypes: cluster1 showed longer overall survival (OS) and stronger immune infiltration compared to cluster2. The pivotal differential genes between the two clusters are SYK, whose pro-carcinogenic mechanism relies in the promotion of AML cell survival and drug resistance 3 , and TLR4 which is thought to modulate lysosomal function and is in turn degraded by lysosome themselves 4 . Finally, a prognostic model consisting of six genes identified patients in a low-risk group who survived significantly longer than those in the high-risk group and had higher immune infiltration and stronger response to immunotherapy.Further, Song J. and colleagues unravel the role of SET-CAN/NUP214 fusion in leukemia. This aberration mainly occurs in T-cell acute lymphoblastic leukemia (T-ALL) patients, but it has also been reported in other leukemias including AML, MPAL and B-ALL. Leukemias bearing this fusion often share common immunophenotypic markers such as: CD7, cCD3, CD34, CD33 and CD13. This supports a model where the transformation of SET-CAN/NUP214+ leukemia may occur in the early stage of myeloid or lymphocyte differentiation, and it may be related to the inhibition of differentiation of primitive progenitor cells by the fusion gene. Patients with SET-CAN/NUP214 fusion usually exhibit resistance to chemotherapy, including glucocorticoids in the early stages of induction therapy, however the overall CR rate is not affected.In another original paper, Liang T. et al focus on the pathogenic role of RAS mutations in AML, and their impact on cell metabolism. In fact, RAS gene mutations are prevalent in AML, and the RAS signaling pathway is closely related to many metabolic pathways. By using a Ba/F3 cell line model transduced with NRAS Q61K and KRAS G12V mutations, the authors conducted a DEG analysis between mutant and wild-type cell lines. They found 1899 DEGs, of which 1089 were related to metabolic pathways, particularly the DGKzeta and PLA2G4A genes in the glycerophospholipid metabolism pathway were significantly upregulated. These findings may contribute to new precision therapy strategies and the development of new therapeutic drugs for AML.In a comprehensive review, Zhou J. et al provide a detailed summary of single-cell sequencing strategies in AML. These techniques ha -Abstract Truncated-
oncology